Group 1 - Municipality Finance Plc issues SEK 500 million notes with a maturity date of 28 December 2027, bearing interest at a floating rate of 3-month Stibor plus 13 basis points per annum [1] - The notes are part of MuniFin's EUR 50 billion debt issuance program, with public trading expected to commence on 7 May 2025 on the Helsinki Stock Exchange [2] - Danske Bank A/S acts as the Dealer for the issuance of the notes [3] Group 2 - MuniFin serves a diverse customer base including municipalities, joint municipal authorities, and entities focused on socially responsible investments such as public transportation and healthcare facilities [4] - The company operates in a global business environment and is recognized as the first Finnish issuer of green and social bonds, with funding guaranteed by the Municipal Guarantee Board [5]

Core Insights - Hexagon Purus faced significant challenges in Q1 2025, with a 44% decline in quarterly revenue to NOK 230 million compared to the same quarter last year, primarily due to lower activity in hydrogen infrastructure and heavy-duty mobility applications [1][2] - The company is implementing cost-reduction measures to achieve profitability at lower volumes and extend its cash runway towards EBITDA and cash flow break-even [1][19] Financial Performance - Total operating expenses for Q1 2025 were NOK 472 million, leading to an EBITDA of NOK -242 million, reflecting an EBITDA margin of -105% [3][8] - Restructuring costs and other non-recurring items accounted for approximately NOK 65 million in the quarter, with adjusted EBITDA at NOK -177 million, equivalent to a -77% margin [3][8] - Total assets decreased to NOK 4,503 million, with total equity at NOK 1,676 million, resulting in an equity ratio of 37% [4][6] Inventory and Cash Flow - Inventory increased to NOK 658 million, primarily consisting of raw materials and work-in-progress items, while trade receivables decreased to NOK 275 million [5] - Net cash flow from operating activities was NOK -183 million, with a release of working capital amounting to NOK 45 million driven by reductions in inventory and accounts receivables [7] Segment Performance - Hydrogen Mobility and Infrastructure (HMI) segment revenue was NOK 204 million, down 47% year-over-year, with an EBITDA of NOK -143 million and a margin of -70% [11][12] - Battery Systems and Vehicle Integration (BVI) segment revenue grew by 35% year-over-year to NOK 25 million, with an EBITDA of NOK -54 million [14][15] Outlook and Strategic Initiatives - The company anticipates continued uncertainty due to recent changes in US policy and international trade, impacting the near-term outlook [16] - Despite challenges, there is strong commercial momentum for hydrogen transit buses in Europe, and incoming order activity for hydrogen infrastructure has improved [17] - The company is focused on cost reduction and reviewing its business portfolio to ensure sustainability until it reaches EBITDA and cash break-even [19]

一、证券市场回顾 南财金融终端数据显示，上周(4月28日—4月30日,下同)，上证综指周内下跌0.49%，收于3279.03点，最 高3296.93点；深证成指周内下跌0.17%，收于9899.82点，最高9926.9点；创业板指周内上涨0.04%，收 于1948.03点，最高1954.62点。在全球市场中，主要指数均上涨。纳斯达克综指上涨3.42%，道琼斯工 业指数上涨3.0%，标普500上涨2.92%。亚太地区，恒生指数上涨2.38%，日经225指数上涨3.15%。 二、新股申购情况 四、基金发行情况 上周有8只新基金发行,分别为:中金消费升级C、泰康稳健双利债券D、泰康招享混合D、兴全天添益货 币C、博时沪深300指数I、上银中债1-3年农发行债券指数C、财通资管康泽稳健养老目标一年持有混合 (FOF)Y、财通资管康恒平衡养老目标三年持有混合发起式(FOF)Y,详情见下表： | 使用 | 基金名称 -10000 | 发行公告日 | 提资类型 | 基全提理 | 基金公司 | | --- | --- | --- | --- | --- | --- | | 024196.OF | 中全海餐件展C | 2025 ...

Ford (F) Q1 2025 Earnings Call May 05, 2025 05:00 PM ET Company Participants Lynn Antipas Tyson - Chief Investor Relations OfficerJames Farley - President & CEOKumar Galhotra - Chief Operating OfficerSherry House - CFOAndrew Frick - President - Ford Blue and Model e, Interim Head - Ford ProAdam Jonas - Head of Global Auto & Shared Mobility ResearchJoseph Spak - Managing DirectorJohn Murphy - Managing DirectorCathy O’Callaghan - President & CEO - Ford Motor Credit Company Conference Call Participants Emmanue ...

Ford (F) Q1 2025 Earnings Call May 05, 2025 05:00 PM ET Speaker0 Good day, everyone. My name is Leila, and I will be your conference operator today. At this time, I would like to welcome you to the Ford Motor Company First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you would like to ask a question during this time, please click on the raise hand icon, whi ...

Core Insights - The NEXUS TRIOMPHE trial data shows a 63% reduction in Major Adverse Event (MAE) rates compared to the reference performance goal, indicating significant clinical improvement for patients with chronic aortic dissection [1][3]. Clinical Outcomes - The trial involved a cohort of 54 patients at high risk for open surgical repair, demonstrating a MAE rate of 13% against a performance goal of 35% (p < 0.001) [4]. - Technical failure rates were reported at 1.9%, significantly lower than the 30% performance goal (p < 0.001) [4]. Device Performance - The NEXUS device is presented as a minimally invasive alternative to open aortic arch replacement, particularly beneficial for high-risk patients [5]. - The trial results are expected to support the clinical module of the PMA filing after one year of follow-up with the primary cohort [6]. Company Overview - Artivion, Inc. specializes in medical devices for cardiac and vascular surgery, focusing on aortic diseases, and markets products in over 100 countries [7].

Core Points - Sequel Pharma has signed an agreement with a leading CDMO for the manufacturing of Kinlytic, a biologic drug for dissolving blood clots [1][4] - Sequel Pharma is committed to funding the return of Kinlytic to global markets, targeting the $400 million U.S. market for catheter clearance [2] - Kinlytic is an enzyme derived from human cell cultures, already approved for clinical use in the U.S., and the goal is to validate new manufacturing processes for re-entry into the market [3][5] Company Overview - Microbix Biosystems Inc. specializes in creating proprietary biological products for human health, with annualized sales targeting C$2.0 million per month [7] - The company produces critical ingredients for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products [7][8] - Microbix is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada [7]

Core Points - Pharma Equity Group A/S held its Annual General Meeting on April 16, 2025, where various proposals were discussed and adopted [1][6] Group 1: Board of Directors' Report - The former CEO, Thomas Kaas Selsø, presented the Board's report on the Company's activities over the past year, addressing shareholder questions regarding the Market Maker agreement with Danske Bank and the potential delisting from Nasdaq Copenhagen [3][4] - Shareholders expressed concerns about the declining share price, attributing it to large shareholders selling their shares, while also acknowledging the Company's successful financing in 2024 and positive research results [4][5] Group 2: Financial Proposals - The audited 2023 annual report was presented, and the discharge of the Board and Executive Management was proposed, with no objections raised from shareholders [8][11] - The expected revenue for the current financial year was projected at DKK 11 million, based on valuations prepared by Baker Tilly and reviewed by Danske Bank [9] - Outstanding convertible loans were confirmed to total approximately DKK 13 million [10] Group 3: Remuneration and Board Elections - The remuneration for the Board of Directors for the 2025 financial year was proposed, with the Chairman receiving DKK 350,000 and Board members receiving DKK 150,000 [14] - All current Board members were re-elected, and two new members, Troels Peter Troelsen and Charlotte Pahl, were elected [16][17] - BDO Statsautoriseret Revisionsaktieselskab was re-elected as the Company's auditor [18] Group 4: Proposals and Authorizations - Three proposals from the Board were discussed, requiring different majorities for adoption, and all were approved without objections [19][20] - The chairman was authorized to file the adopted resolutions with the Danish Business Authority [21] Group 5: Company Overview - Pharma Equity Group A/S is dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S, with a focus on healthcare and innovative medical solutions [23][24]

Core Points - United Airlines has cut 35 daily round-trip flights at Newark Liberty International Airport due to FAA technology failures and staffing issues, resulting in excessive delays [1][2] - The cancellations represent about 10% of United's service at Newark, following a significant walkout of FAA air traffic controllers due to malfunctioning technology [2][6] - CEO Scott Kirby expressed disappointment over the cuts but emphasized the necessity to protect customers amid ongoing FAA staffing issues [3][4] Technology and Staffing Issues - Over 20% of FAA controllers for Newark Airport walked off the job due to technology failures, leading to numerous flight diversions and cancellations [6][4] - The FAA has not provided details on the staffing and technology problems affecting the Philadelphia Terminal Radar Approach Control, which serves Newark [10] - Transportation Secretary Sean Duffy acknowledged the outdated technology causing equipment outages and emphasized the need for a new air traffic control system [11] Impact on Operations - Recent technology failures have caused significant delays, with one United flight delayed by over five hours and another El Al flight delayed by nearly 13 hours [7] - The FAA has implemented a Ground Delay for Newark, with average delays of 127 minutes for incoming flights [7] - The New Jersey Port Authority has urged the FAA to address staffing shortages and accelerate technology upgrades to alleviate delays in the busy air corridor [8][10] Recommendations and Future Actions - Kirby has called for Newark to be designated as a Level 3 slot-controlled airport, indicating its inability to handle high traffic volumes effectively [12] - The Port Authority has invested billions in modernizing Newark Liberty, but improvements are contingent on a fully staffed and modern federal air traffic system [10]

Core Viewpoint - HPQ Silicon Inc. has filed its audited annual financial statements and related documents for the fiscal year ended December 31, 2024, and is now focusing on addressing inquiries from the Quebec regulatory authority to lift a temporary trading halt [1][2]. Group 1: Company Developments - The Required Filing was completed in French to comply with the regulations of Quebec's L'Autorité des Marchés Financiers (AMF), with an English version to follow [2]. - The company confirms that there are no ongoing legal proceedings against it and that all material information has been disclosed [3]. Group 2: Company Overview - HPQ Silicon Inc. is a Quebec-based Tier 1 Industrial Issuer on the TSX Venture Exchange, focusing on developing green processes for critical materials to achieve net zero emissions [4]. - The company collaborates with technology partners PyroGenesis Canada Inc. and NOVACIUM SAS to advance its initiatives [4]. Group 3: Strategic Pillars - HPQ aims to become a low-cost manufacturer of Fumed Silica using its proprietary FUMED SILICA REACTOR technology [6]. - The company is working on producing silicon-based anode materials for battery applications with NOVACIUM SAS's assistance [6]. - An affiliate of HPQ, NOVACIUM SAS, is developing a low carbon, chemical-based hydrogen production system [6]. - Another initiative involves transforming black aluminum dross into a valuable resource [6]. - HPQ is also focused on becoming a zero CO2 producer of High Purity Silicon using its PUREVAP "Quartz Reduction Reactors" technology [6].